Results 161 to 170 of about 1,443,667 (357)

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3) [PDF]

, 2001
Rainer Riesenberg, Alexander Büchner, Heike Pohla, Horst Lindhofer   +3 more
openalex   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

International Journal of Nanomedicine, 2018
Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction ...
Pan H, Liu J, Deng W, Xing J, Li Q, Wang Z   +5 more
doaj  

Efficient Antibody Structure Refinement Using Energy-Guided SE(3) Flow Matching [PDF]

arXiv
Antibodies are proteins produced by the immune system that recognize and bind to specific antigens, and their 3D structures are crucial for understanding their binding mechanism and designing therapeutic interventions. The specificity of antibody-antigen binding predominantly depends on the complementarity-determining regions (CDR) within antibodies ...
arxiv  

Depletion of CCR5-Expressing Cells with Bispecific Antibodies and Chemokine Toxins: A New Strategy in the Treatment of Chronic Inflammatory Diseases and HIV [PDF]

, 2001
Hilke Brühl, Josef Cihak, M. Stangassinger, Detlef Schlöndorff, Matthias Mack   +4 more
openalex   +1 more source

Furmonertinib in uncommon EGFR‐mutated non‐small cell lung cancer with central nervous system metastases: A retrospective cohort study

International Journal of Cancer, EarlyView.
What's New? Mutations in EGFR are the most frequently detected driver mutations in non‐small cell lung carcinoma (NSCLC), and two common mutations account for 75%–90% of these. The remaining 10%–25% are uncommon mutations, a heterogeneous set of genetic changes that do not necessarily respond well to treatment.
Yuwen Xie, Hehui Fang, Wanwan Cheng, Ting Xu, Shu Xu, Chuanyong Yu, Yong Liu, Shencun Fang   +7 more
wiley   +1 more source

Energy-based generative models for monoclonal antibodies [PDF]

arXiv
Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite advances in biotechnology that accelerated the development of antibody drugs, the drug discovery process for this modality remains ...
arxiv  

Bispecific Monoclonal Antibodies Mediate Binding of Dengue Virus to Erythrocytes in a Monkey Model of Passive Viremia [PDF]

, 2001
Chang S. Hahn, Olivia G. French, Patricia L. Foley, Edward N. Martin, Ronald P. Taylor   +4 more
openalex   +1 more source

Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell linesin vitro andin vivo [PDF]

, 2001
C. H. J. Ford, Perry A. Osborne, Beatriz Rego, A. Mathew   +3 more
openalex   +1 more source

An engineered bispecific human monoclonal antibody against SARS-CoV-2

Nature Immunology, 2022
Z. Li, Shihua Li, Geng Zhang, Weiyu Peng, Zhen Chang, Xue Zhang, Z. Fan, Y. Chai, Feiran Wang, Xin Zhao, Dedong Li, Rong Zhang, Zhanlong He, Weiwei Zou, K. Xu, W. Lei, Peipei Liu, Junfeng Hao, Jingjing Zhang, Litao Sun, Guizhen Wu, Shuguang Tan, G. Gao, F. Gao, Yan Wu   +24 more
semanticscholar   +1 more source